Topotecan for recurrent cervical cancer after platinum-based therapy

International Journal of Gynecological Cancer

Volumn 10, Issue 4, 2000, Pages 285-288

  Abu Rustum, N R ^a   Lee, S ^a   Massad, L S ^a  

^a Jr Hospital of Cook County   (United States)

Author keywords

Cervical cancer; Chemotherapy; Topotecan; Toxicity

Indexed keywords

CARBOPLATIN; CISPLATIN; HEMOPOIETIC GROWTH FACTOR; IFOSFAMIDE; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CLINICAL ARTICLE; CONTROLLED STUDY; ERYTHROCYTE TRANSFUSION; FEMALE; FEVER; HUMAN; HYPERPIGMENTATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; VOMITING;

EID: 0033823163     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1438.2000.010004285.x     Document Type: Article

References (12)

1. Topotecan in the treatment of gynecologic cancer
2. Prediction of creatinine clearance from serum creatinine
3. Life-threatening myelosuppression in patients with renal impairment receiving topotecan
4. Clinical guidelines for managing topotecan-related hematologic toxicity
5. Chemotherapy in the management of advanced or recurrent cervical and endometrial carcinoma
6. Chemotherapy for cervical cancer
7. Phase II study of irinotecan in prior chemotherapy-treated squamous cell cancer of the cervix
8. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group phase II trial of first-line irinotecan in patients with advanced or recurrent squamous cell carcinoma of the cervix
9. Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer
10. Phase II trial of topotecan for cervical cancer of the uterus
11. Phase II trial of topotecan with cisplatin in squamous and non-squamous cervical cancer: Preliminary results